Skip to main content

Table 3 Pairwise meta-analyses for efficacies of different CCRT regimens in the treatment of LA-NSCLC

From: A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer

Included studies

Comparisons

Efficacy events

Pairwise meta-analysis

Treatment 1

Treatment 2

OR (95% CI)

I2

P

ORR

 3 studies

K VS. R

84/174

95/176

0.80 (0.52–1.21)

0.0%

0.756

 2 studies

F VS. I

34/56

29/56

1.44 (0.68–3.05)

0.0%

0.935

 2 studies

I VS. K

99/173

92/176

1.22 (0.80–1.86)

84.0%

0.012

 1 study

A VS. B

21/33

26/32

0.40 (0.13–1.26)

NA

NA

 1 study

A VS. D

90/272

102/283

0.88 (0.62–1.25)

NA

NA

 1 study

A VS. E

40/50

44/55

1.00 (0.38–2.61)

NA

NA

 1 study

A VS. M

70/95

62/96

1.54 (0.83–2.85)

NA

NA

 1 study

B VS. G

96/151

102/153

0.87 (0.54–1.40)

NA

NA

 1 study

B VS. N

96/151

86/152

1.34 (0.84–2.12)

NA

NA

 1 study

C VS. D

1/9

6/13

0.15 (0.01–1.53)

NA

NA

 1 study

D VS. H

46/52

44/48

0.70 (0.18–2.64)

NA

NA

 1 study

E VS. G

78/99

71/101

1.57 (0.82–2.99)

NA

NA

 1 study

G VS. N

102/153

86/152

1.53 (0.96–2.44)

NA

NA

 1 study

F VS. H

28/35

22/31

1.64 (0.53–5.09)

NA

NA

 1 study

K VS. L

16/101

29/99

0.45 (0.23–0.90)

NA

NA

 1 study

K VS. O

24/47

44/60

0.38 (0.17–0.85)

NA

NA

 1 study

K VS. P

56/66

60/65

0.47 (0.15–1.45)

NA

NA

 1 study

K VS. Q

14/20

18/21

0.39 (0.08–1.84)

NA

NA

1-year OS rate

 3 studies

K VS. R

110/174

119/176

0.82 (0.53–1.28)

0.0%

0.962

 2 studies

A VS. B

39/64

49/76

0.86 (0.43–1.71)

72.4%

0.057

 2 studies

F VS. I

50/56

47/56

1.60 (0.53–4.83)

0.0%

0.995

 1 study

A VS. D

209/272

215/283

1.05 (0.71–1.55)

NA

NA

 1 study

A VS. E

45/50

45/55

2.00 (0.63–6.32)

NA

NA

 1 study

A VS. M

71/95

77/96

0.73 (0.37–1.44)

NA

NA

 1 study

B VS. G

121/151

116/153

1.29 (0.75–2.22)

NA

NA

 1 study

B VS. N

121/151

114/152

1.34 (0.78–2.31)

NA

NA

 1 study

D VS. H

44/52

37/48

1.64 (0.60–4.49)

NA

NA

 1 study

E VS. G

17/99

32/101

0.45 (0.23–0.87)

NA

NA

 1 study

G VS. N

116/153

114/152

1.05 (0.62–1.76)

NA

NA

 1 study

F VS. H

27/35

23/31

1.17 (0.38–3.62)

NA

NA

 1 study

I VS. K

52/88

23/88

4.08 (2.16–7.72)

NA

NA

 1 study

K VS. L

26/101

26/99

0.97 (0.52–1.83)

NA

NA

 1 study

K VS. O

12/47

28/60

0.39 (0.17–0.90)

NA

NA

 1 study

K VS. P

45/66

48/65

0.76 (0.36–1.62)

NA

NA

2-year OS rate

 2 studies

A VS. B

23/64

24/76

1.22 (0.60–2.46)

71.4%

0.061

 2 studies

K VS. R

48/151

62/153

0.68 (0.43–1.10)

16.7%

0.273

 2 studies

F VS. I

41/56

26/56

3.15 (1.43–6.96)

0.0%

0.854

 1 study

A VS. D

141/272

147/283

1.00 (0.71–1.39)

NA

NA

 1 study

A VS. E

36/50

24/55

3.32 (1.47–7.51)

NA

NA

 1 study

A VS. M

46/95

41/96

1.26 (0.71–2.23)

NA

NA

 1 study

B VS. G

71/151

73/153

0.97 (0.62–1.53)

NA

NA

 1 study

B VS. N

71/151

61/152

1.32 (0.84–2.09)

NA

NA

 1 study

D VS. H

28/52

27/48

0.91 (0.41–2.00)

NA

NA

 1 study

E VS. G

39/99

52/101

0.61 (0.35–1.07)

NA

NA

 1 study

F VS. H

18/35

15/31

1.13 (0.43–2.97)

NA

NA

 1 study

G VS. N

73/153

61/152

1.36 (0.86–2.14)

NA

NA

 1 study

I VS. K

19/88

4/88

5.78 (1.88–17.80)

NA

NA

 1 study

K VS. L

4/101

9/99

0.42 (0.12–1.40)

NA

NA

 1 study

K VS. O

6/47

15/60

0.43 (0.15–1.21)

NA

NA

 1 study

K VS. P

17/66

28/65

0.46 (0.22–0.96)

NA

NA

3-year OS rate

 2 studies

F VS. I

27/56

13/56

3.08 (1.37–6.94)

0.0%

0.921

 2 studies

K VS. R

14/151

30/153

0.42 (0.21–0.83)

0.0%

0.412

 1 study

A VS. B

11/33

4/32

3.50 (0.98–12.50)

NA

NA

 1 study

A VS. D

101/272

113/283

0.89 (0.63–1.25)

NA

NA

 1 study

A VS. E

29/50

17/55

3.09 (1.38–6.88)

NA

NA

 1 study

A VS. M

39/95

25/96

1.98 (1.07–3.65)

NA

NA

 1 study

B VS. G

40/151

54/153

0.66 (0.40–1.08)

NA

NA

 1 study

B VS. N

40/151

37/152

1.12 (0.67–1.88)

NA

NA

 1 study

D VS. H

23/52

15/48

1.74 (0.77–3.96)

NA

NA

 1 study

E VS. G

62/99

61/101

1.10 (0.62–1.94)

NA

NA

 1 study

F VS. H

12/35

10/31

1.10 (0.39–3.06)

NA

NA

 1 study

G VS. N

54/153

37/152

1.70 (1.03–2.79)

NA

NA

 1 study

I VS. K

9/88

2/88

4.90 (1.03–23.37)

NA

NA

 1 study

K VS. L

1/101

2/99

0.49 (0.04–5.44)

NA

NA

 1 study

K VS. O

4/47

9/60

0.53 (0.15–1.83)

NA

NA

 1 study

K VS. P

7/66

15/65

0.40 (0.15–1.05)

NA

NA

  1. A, CCRT (cisplatin + etoposide); B, CCRT (carboplatin + paclitaxel); C, CCRT (pemetrexed + carboplatin); CCRT Concurrent chemoradiotherapy, CI Confidence interval; D, CCRT (pemetrexed + cisplatin); E, CCRT (docetaxel + cisplatin); F, CCRT (S-1 + cisplatin); G, CCRT (mitomycin + vindesine + cisplatin); H, CCRT (cisplatin + vinorelbine); I, CCRT (cisplatin); K, RT; L, CCRT (5-FU); LA-NSCLC Locally advanced non-small cell lung cancer; M, CCRT (paclitaxel + cisplatin); N, CCRT (irinotecan + carboplatin); NA Not available; O, CCRT (nedaplatin); OR Odds radios, ORR Overall response rate; P, CCRT (carboplatin + etoposide); Q, CCRT (paclitaxel); R, CCRT (carboplatin)